Draft drugs Bill may let pharma firms compound minor quality and labelling offences
India’s proposed Drugs, Medical Devices and Cosmetics Bill, 2026 would allow compounding of six specified minor compliance offences, while retaining severe prison terms and fines for adulterated or spurious drugs. The draft has not yet been introduced in Parliament.
What happened
India’s draft Drugs, Medical Devices and Cosmetics Bill, 2026 would allow compounding of specified minor quality, labelling, clinical-trial and device
Key facts
- Six offence categories proposed for compounding
- Compounding amount capped at the maximum prescribed fine
- Serious adulterated/spurious drug offences: minimum 10 years' imprisonment, up to life; minimum Rs 10 lakh fine or three times confiscated drug value
- Other spurious-drug offences: minimum seven years' imprisonment, up to life; minimum Rs 5 lakh fine or three times confiscated drug value
Why this matters
Acquirers should factor potentially lower exposure for minor compliance breaches into India diligence models while continuing to scrutinize any history of adulterated, spurious or otherwise serious product violations.
What to watch
- Formal introduction of the Drugs, Medical Devices and Cosmetics Bill, 2026 in Parliament.
- Final text identifying the six compoundable offences, fee structure, repeat-offender treatment, and authority empowered to compound.
- Parliamentary committee recommendations, state-regulator feedback, and industry or patient-group opposition.
- Rules detailing inspection, recall, reporting, and corrective-action requirements after enactment.
- Enforcement data showing whether regulators increase inspections or settlements after the law takes effect.
- Maintain existing GMP, labelling, batch-record, and pharmacovigilance controls; do not treat the draft as a compliance relaxation.
- Map past regulatory observations and classify which incidents could potentially qualify for compounding versus those that retain criminal exposure.
- Prepare a rapid corrective-action and settlement protocol for distributors, pharmacies, manufacturers, and medical-device vendors.
- Review supplier agreements to strengthen indemnities, recall obligations, audit rights, and notification requirements for labelling or quality deviations.
- Track potential pricing and assortment opportunities if compliance-risk premia decline for credible domestic generic and device suppliers.